Back HBV Basic Science

HBV Basic Science

EASL 2012: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap

Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

Read more:

EASL 2012: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon

Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

Read more:

Hepatitis B Therapeutic Vaccine Appears Safe and Stimulates Immune Response

In late December, Dynavax Technologies reported findings from a small early clinical trial showing that its investigational hepatitis B virus (HBV) therapeutic vaccine DV-601 -- intended to help control the virus in people already infected, rather than prevent infection -- was well tolerated and produced immunological and virological responses at all dose levels. Larger studies are needed, however, to show whether the vaccine is clinically effective.

Read more:

Androgens Promote Hepatitis B Virus Replication, Helping Explain Sex Differences

The hepatitis B virus (HBV) carries receptors for androgens -- male hormones such as testosterone -- which may help explain why men are more likely than women to develop chronic hepatitis B and experience more aggressive liver disease, according to study findings reported in the February 2012 Journal of Virology.alt

Read more:

Sex Hormone Receptor May Explain Higher Risk of Hepatocellular Carcinoma in Men

Interaction between hepatitis B virus (HBV) and the androgen receptor in the liver promotes viral replication and triggers cell changes that lead to development of hepatocellular carcinoma, according to a study in mice described in the May 19, 2010 issue of Science Translational Medicine. Since men have more active androgen receptors than women, these findings help explain why men with hepatitis B are more prone to liver cancer, and suggest that blocking androgen receptors in the liver might be an effective treatment.

Read more: